Men's Health News

RSS

Segasist Technologies receives HTX funding for clinical validation of prostate MRI software

Segasist Technologies, a Canadian software company developing contouring productivity tools for medical imaging, has today announced the receipt of funding from The Health Technology Exchange (HTX) towards support of clinical validation of its software, to be conducted at the Lawson Health Research Institute and London Health Sciences Centre (London, Ontario). Experts from Sunnybrook Research Institute and Sunnybrook Health Sciences Centre will also participate in the validation process by providing input in the form of gold standard contours.

26 Nov 2010

HIV treatment drugs also help prevent HIV infection in high-risk men: Study

In a significant advance for HIV prevention research, a clinical trial confirms that the same drugs used for treating HIV can also help prevent HIV infection in the first place.

24 Nov 2010

Daily oral antiretroviral reduces HIV infection risk in MSM by 44%, study finds

A study that included nearly 2,500 HIV-negative men and transgender women who have sex with men has shown that a daily dose of Truvada, a pill containing the AIDS drugs emtricitabine and tenofovir, "can reduce risk of contracting [HIV] by an average of 44% - and by more than 70% if the subjects" follow the regimen closely, Los Angeles Times reports (Maugh, 11/23).

24 Nov 2010

Men failing to protect eyes from injuries: Experts

A review looking at patients attending a Melbourne hospital’s emergency department with a serious eye injury shows that most of them could be prevented by proper eye protection. Men’s particular lack of eye protection while using power tools and lawn mowers, usually during routine house maintenance, were the other major factors in the injury cases say the researchers.

23 Nov 2010

Study finds no link between prostate cancer clinical stage and risk of recurrence after radical prostatectomy

A new study challenges the current staging system that determines the extent or severity of prostate cancer that has not metastasized. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study found that there is no link between localized prostate cancer's clinical stage and a patient's risk of cancer recurrence after having his prostate removed.

22 Nov 2010

DoD recommends funding for Synta's STA-9584 for prostate cancer study

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Department of Defense (DoD) has recommended STA-9584, a novel vascular disrupting agent (VDA) currently in pre-clinical development at Synta, be funded for study in advanced prostate cancer.

19 Nov 2010

Expert panel to endorse newly approved therapeutic vaccine for advanced prostate cancer

Provenge is one step closer to being covered by Medicare. An expert panel voted Wednesday to endorse the newly approved therapeutic vaccine for men with advanced prostate cancer.

19 Nov 2010

Multidisciplinary clinic approach can improve survival in patients with aggressive prostate cancer

A research team from the National Cancer Institute (NCI) designated Kimmel Cancer Center (KCC) at Jefferson has concluded for the first time that a multidisciplinary clinic approach to aggressive prostate cancer can improve survival in patients. The results from the 15-year study of the multidisciplinary clinic can be found in the November issue of Journal of Oncology Practice.

18 Nov 2010

New anti-cancer drug targeting vitamin D receptor reduces PSA level in HRPC

A new anti-cancer drug aimed at vitamin D receptors on cancer cells has prompted encouraging responses in the levels of PSA (prostate specific antigen) in men with prostate cancer that has become resistant to hormonal therapies.

18 Nov 2010

Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer

Exelixis, Inc. today reported interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

18 Nov 2010

Medicare roundup: Payment cuts irk healthcare industry; officials mull new prostate-cancer treatment

Doctors across the United States are taking a wait-and-see approach while Congress decides whether or not to allow a scheduled 23% cut in Medicare reimbursement rates to take effect on Dec. 1.

17 Nov 2010

HUPTI's first group of patients complete prostate cancer treatment

The Hampton University Proton Therapy Institute's first group of patients completed their course of treatment for prostate cancer.

16 Nov 2010

Men treated with hormone-based therapy for prostate cancer face higher risk of colorectal cancer: Study

Men treated with hormone-based therapy for prostate cancer faced a 30 percent to 40 percent higher risk of colorectal cancer, compared to patients who did not receive this treatment, according to a new study.

16 Nov 2010

GTx presents preclinical studies of GTx-758 and GTx-230 for treatment of cancer

GTx, Inc. announced the presentation of preclinical studies evaluating GTx-758, a selective estrogen receptor alpha agonist being developed for first line treatment of advanced prostate cancer, and GTx-230, a novel microtubule polymerization inhibitor.

15 Nov 2010

Light alcohol consumption benefits post-coronary bypass patients

Light to moderate alcohol consumption (about two to three drinks daily) among male coronary artery bypass patients was associated with 25 percent fewer subsequent cardiovascular procedures, heart attacks, strokes and death compared to non-drinkers, in a study presented at the American Heart's Association's Scientific Sessions 2010.

15 Nov 2010

Hartford Hospital research team receives $238,000 grant from InHealth to study prostate cancer

The Institute for Health Technology Studies (InHealth) has awarded a grant totaling more than $238,000 to a research team at the Helen & Harry Gray Cancer Center at Hartford Hospital in Connecticut to study how various prostate cancer treatments affect a patient's "social capital" the ability to continue working productively in a paying job.

12 Nov 2010

$Androgen deprivation therapy may increase fracture risk in older men with localized prostate cancer: Research$

Androgen deprivation therapy may increase fracture risk in older men with localized prostate cancer: Research

Research presented today at a national conference by a team of investigators at The Cancer Institute of New Jersey (CINJ), shows careful consideration should be given before initiating androgen deprivation therapy, a common treatment for older men with localized prostate cancer.

11 Nov 2010

Using mild painkillers during pregnancy can increase risk of male reproductive disorders

New evidence has emerged that the use of mild painkillers such as paracetamol, aspirin and ibuprofen, may be part of the reason for the increase in male reproductive disorders in recent decades.

10 Nov 2010

New study reveals finger length can indicate high testosterone levels

Potential investors might wish to examine the fingers of their financial advisor prior to signing over any savings. A new study from Concordia University has found the length between the second and fourth finger is an indicator of high levels of prenatal testosterone, risk-taking and potential financial success in men.

10 Nov 2010

$Long-term androgen deprivation therapy increases risk of fracture in older men with prostate cancer$

Long-term androgen deprivation therapy increases risk of fracture in older men with prostate cancer

Men with history of fracture and comorbidities are at an increased risk of fracture after long-term use of androgen deprivation therapy, and initiating this therapy should be carefully considered in older men with localized prostate cancer.

9 Nov 2010

Men's Health News

Segasist Technologies receives HTX funding for clinical validation of prostate MRI software

HIV treatment drugs also help prevent HIV infection in high-risk men: Study

Daily oral antiretroviral reduces HIV infection risk in MSM by 44%, study finds

Men failing to protect eyes from injuries: Experts

Study finds no link between prostate cancer clinical stage and risk of recurrence after radical prostatectomy

DoD recommends funding for Synta's STA-9584 for prostate cancer study

Expert panel to endorse newly approved therapeutic vaccine for advanced prostate cancer

Multidisciplinary clinic approach can improve survival in patients with aggressive prostate cancer

New anti-cancer drug targeting vitamin D receptor reduces PSA level in HRPC

Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer

Medicare roundup: Payment cuts irk healthcare industry; officials mull new prostate-cancer treatment

HUPTI's first group of patients complete prostate cancer treatment

Men treated with hormone-based therapy for prostate cancer face higher risk of colorectal cancer: Study

GTx presents preclinical studies of GTx-758 and GTx-230 for treatment of cancer

Light alcohol consumption benefits post-coronary bypass patients

Hartford Hospital research team receives $238,000 grant from InHealth to study prostate cancer

Androgen deprivation therapy may increase fracture risk in older men with localized prostate cancer: Research

Using mild painkillers during pregnancy can increase risk of male reproductive disorders

New study reveals finger length can indicate high testosterone levels

Long-term androgen deprivation therapy increases risk of fracture in older men with prostate cancer

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Latest News